These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 5289372)

  • 1. Decrease of the 3,4-dihydroxyphenylalanine (DOPA) decarboxylase activities in human erythrocytes and mouse tissues after administration of DOPA.
    Tate SS; Sweet R; McDowell FH; Meister A
    Proc Natl Acad Sci U S A; 1971 Sep; 68(9):2121-3. PubMed ID: 5289372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of chronic L-DOPA administration of catecholamine metabolism in the rat.
    Lancaster J; Sawyer PR; Shepherd DM; Turnbull MJ
    Br J Pharmacol; 1973 Apr; 47(4):838-42. PubMed ID: 4723802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decrease in liver aromatic L-amino-acid decarboxylase produced by chronic administration of L-dopa.
    Dairman W; Christenson JG; Udenfriend S
    Proc Natl Acad Sci U S A; 1971 Sep; 68(9):2117-20. PubMed ID: 5289371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor].
    Christiani K; Möller WD
    Munch Med Wochenschr; 1973 Apr; 115(16):711-3. PubMed ID: 4197759
    [No Abstract]   [Full Text] [Related]  

  • 5. Peripheral aromatic L-amino acids decarboxylase inhibitor in Parkinsonism. I. Effect on O-methylated metabolites of L-dopa-2- 14 C.
    Messiha FS; Hsu TH; Bianchine JR
    J Clin Invest; 1972 Feb; 51(2):452-5. PubMed ID: 5009125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of DOPA-2- 14 C in relation to DOPA-1- 14 C (carboxyl- 14 C-labelled DOPA) in mice before and after inhibition of DOPA-decarboxylase, studied by whole-body autoradiography.
    Tjälve H; Ullberg S
    Arch Int Pharmacodyn Ther; 1972 Oct; 199(2):376-88. PubMed ID: 4627124
    [No Abstract]   [Full Text] [Related]  

  • 7. Parkinson's disease: activity of L-dopa decarboxylase in discrete brain regions.
    Lloyd K; Hornykiewicz O
    Science; 1970 Dec; 170(3963):1212-3. PubMed ID: 5478194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of chronic administration of L-dopa on catechol-O-methyltransferase in rat tissues.
    Sharpless NS; Tyce GM; Owen CA
    Life Sci I; 1973 Feb; 12(3):97-106. PubMed ID: 4696602
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of Parkinson's disease with L-dopa and with a combination of L-dopa and dopa-decarboxylase inhibitor].
    Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Zamponi A
    Minerva Med; 1972 Dec; 63(89):4853-61. PubMed ID: 4566743
    [No Abstract]   [Full Text] [Related]  

  • 10. L-glutamic acid decarboxylase in Parkinson's disease: effect of L-dopa therapy.
    Lloyd KG; Hornykiewicz O
    Nature; 1973 Jun; 243(5409):521-3. PubMed ID: 4743649
    [No Abstract]   [Full Text] [Related]  

  • 11. Morphological and biochemical studies on liver biopsies of parkinsonian patients treated with levodopa and decarboxylase inhibitor.
    Nevalainen T; Riekkinen P; Rinne UK; Sonninen V
    Acta Neurol Scand; 1974; 50(1):122-30. PubMed ID: 4365556
    [No Abstract]   [Full Text] [Related]  

  • 12. L-dopa therapy in parkinsonism: mechanism of action.
    Sandler M
    Psychiatr Neurol Neurochir; 1971; 74(4):331-3. PubMed ID: 5146239
    [No Abstract]   [Full Text] [Related]  

  • 13. Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor.
    Klawans HL; Ringel SP; Shenker DM
    J Neurol Neurosurg Psychiatry; 1971 Dec; 34(6):682-6. PubMed ID: 5158783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa?].
    Gauthier G; de Ajuriaguerra J; Geissbuhler F; Simona B; Constantinidis J; Yanniotis G; Krassoievitch M; Eisenring JJ; Tissot R
    Presse Med (1893); 1971 Jan; 79(3):91-2. PubMed ID: 5539694
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapy of Parkinson's syndrome with L-dopa only and in combination with a decarboxylase inhibitor. A comparison].
    Feise G; Paal G
    Nervenarzt; 1974 Mar; 45(3):126-32. PubMed ID: 4832035
    [No Abstract]   [Full Text] [Related]  

  • 16. [L-DOPA-and dopa-decarboxylase inhibitor combination for the treatment of Parkinsonism].
    Fujimori N; Kito S; Yamamoto M; Itoga E; Kosaka K
    Nihon Rinsho; 1974 Mar; 32(3):579-86. PubMed ID: 4859014
    [No Abstract]   [Full Text] [Related]  

  • 17. [L-DOPA with the decarboxylase inhibitor Ro 4-4602 in the treatment of Parkinson's disease].
    Lakke JP; Nienhuis RJ; Meyer R; Zwols F; Schut T
    Ned Tijdschr Geneeskd; 1972 Nov; 116(48):2180-4. PubMed ID: 4639072
    [No Abstract]   [Full Text] [Related]  

  • 18. [Therapy of parkinsonian syndromes and plasmatic DOPA levels. Effects of L-DOPA and 3-OMD, administered alone or combined, with or without a decarboxylase inhibitor].
    Geissbühler F; Gaillard JM; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Rev Eur Etud Clin Biol; 1972 Jan; 17(1):38-44. PubMed ID: 5041348
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effect of the combined treatment of Parkinson patients with L-Dopa and a decarboxylase inhibitor (Ro4-4602). Quantitative analysis of bradykinesia by means of reaction time measurements].
    Kaufmann W; Butz P; Wiesendanger M
    Dtsch Z Nervenheilkd; 1970; 197(1):85-100. PubMed ID: 5522871
    [No Abstract]   [Full Text] [Related]  

  • 20. Parkinson's disease: from brain homogenate to treatment.
    Hornykiewicz O
    Fed Proc; 1973 Feb; 32(2):183-90. PubMed ID: 4143953
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.